AU2001292818A1 - Use of transcription factors for treating inflammation and other diseases - Google Patents
Use of transcription factors for treating inflammation and other diseasesInfo
- Publication number
- AU2001292818A1 AU2001292818A1 AU2001292818A AU9281801A AU2001292818A1 AU 2001292818 A1 AU2001292818 A1 AU 2001292818A1 AU 2001292818 A AU2001292818 A AU 2001292818A AU 9281801 A AU9281801 A AU 9281801A AU 2001292818 A1 AU2001292818 A1 AU 2001292818A1
- Authority
- AU
- Australia
- Prior art keywords
- diseases
- transcription factors
- treating inflammation
- inflammation
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23437900P | 2000-09-20 | 2000-09-20 | |
US60234379 | 2000-09-20 | ||
PCT/US2001/029340 WO2002024144A2 (fr) | 2000-09-20 | 2001-09-20 | Utilisation de facteurs de transcription dans le traitement d'inflammation et d'autres maladies |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001292818A1 true AU2001292818A1 (en) | 2002-04-02 |
Family
ID=22881133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001292818A Abandoned AU2001292818A1 (en) | 2000-09-20 | 2001-09-20 | Use of transcription factors for treating inflammation and other diseases |
Country Status (4)
Country | Link |
---|---|
US (1) | US6869929B2 (fr) |
EP (1) | EP1330271A4 (fr) |
AU (1) | AU2001292818A1 (fr) |
WO (1) | WO2002024144A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1663197T3 (pl) * | 2003-09-09 | 2008-09-30 | Biogen Idec Int Gmbh | Zastosowanie pochodnych kwasu fumarowego do leczenia niewydolności serca oraz astmy |
US7485094B2 (en) * | 2003-09-30 | 2009-02-03 | Smithmarks, Inc. | Methods of diagnosis using pulse volume measurement |
WO2007022478A2 (fr) * | 2005-08-17 | 2007-02-22 | The Trustees Of The University Of Pennsylvania Center For Technology Transfer | Facteurs de transcription dans la synthèse dendrites-protéine dendritique neurale et mort cellulaire |
US7763441B2 (en) | 2006-03-13 | 2010-07-27 | Wyeth | Modulators of gluconeogenesis |
US20120053112A1 (en) * | 2009-05-05 | 2012-03-01 | Children's Hospital Medical Center | Methods and compositions related to the regulation of goblet cell differentiation, mucus production and mucus secretion |
US9139829B2 (en) * | 2012-02-28 | 2015-09-22 | Medical Diagnostic Laboratories, Llc | SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840277A (en) * | 1993-03-30 | 1998-11-24 | Charlotte Hospital Authority | Treatment of chronic pulmonary inflammation |
US5463023A (en) * | 1993-10-22 | 1995-10-31 | Washington University | Composition for inhibition of intracellular transcription |
FR2724846B1 (fr) * | 1994-09-27 | 1996-12-20 | Rhone Poulenc Rorer Sa | Methode de traitement des cancers par regulation de l'activite des proteines ras |
WO1997003358A1 (fr) * | 1995-07-07 | 1997-01-30 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Procede pour identifier des inhibiteurs de la voie de transduction de signaux jak-stat |
US5952483A (en) * | 1997-07-31 | 1999-09-14 | Smithkline Beecham Corporation | Human IκB-β |
JPWO2002064165A1 (ja) * | 2001-02-13 | 2004-06-10 | 久光製薬株式会社 | Ets転写因子又はそれをコードする遺伝子からなる細胞増殖抑制剤 |
JP2002241303A (ja) * | 2001-02-13 | 2002-08-28 | Hisamitsu Pharmaceut Co Inc | Ets転写因子又はそれをコードする遺伝子からなる上皮細胞のgm−csf、及び/又はディフェンシン蛋白質の発現調節剤。 |
-
2001
- 2001-09-20 AU AU2001292818A patent/AU2001292818A1/en not_active Abandoned
- 2001-09-20 WO PCT/US2001/029340 patent/WO2002024144A2/fr not_active Application Discontinuation
- 2001-09-20 EP EP01973217A patent/EP1330271A4/fr not_active Withdrawn
-
2003
- 2003-03-20 US US10/393,905 patent/US6869929B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2002024144A2 (fr) | 2002-03-28 |
EP1330271A4 (fr) | 2005-11-09 |
WO2002024144A3 (fr) | 2002-06-06 |
US20030229003A1 (en) | 2003-12-11 |
US6869929B2 (en) | 2005-03-22 |
EP1330271A2 (fr) | 2003-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001259758A1 (en) | Interleukin-1 inhibitors in the treatment of diseases | |
AU2001249918A1 (en) | Inhibitors of inflammation and reperfusion injury and methods of use thereof | |
AU2001275257A1 (en) | Methods and devices for the treatment of urinary incontinence | |
AU2000260550A1 (en) | Treatment of skin damage using polyenylphosphatidylcholine | |
AU7339800A (en) | Ophthalmic device and method of manufacture and use | |
AU2001296638A1 (en) | Nozzle for ultrasound and wound treatment | |
AU2002233643A1 (en) | Methods of treating diseases in association with decrease in the expression of AOP-1 gene or AOP-1 and remedies for the diseases | |
AU2002239491A1 (en) | Methods for the treatment of cancer and other diseases and methods of developing the same | |
AU2002225954A1 (en) | Dipeptidylpeptidases and methods of use | |
AU7748000A (en) | Method and composition for the treatment of dermatologic diseases | |
AU2002240401A1 (en) | Methods and apparatus for treating hemorrhoids and similar ailments | |
AUPQ877300A0 (en) | Topical treatment of skin | |
AU2001269314A1 (en) | Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds | |
AUPQ415899A0 (en) | Compositions for and methods of treatment of allergic diseases | |
AU3622600A (en) | Metalloproteinases and methods of use therefor | |
AU2001278558A1 (en) | Use of co for treating inflammation of upper airways or bronchi | |
AU2002237667A1 (en) | Methods for the treatment and prevention of urinary stone disease | |
AU2001228703A1 (en) | Use of cox-2 inhibitors for the treatment of constipation | |
AU2001268233A1 (en) | Compositions and methods for treating neoplastic disease using inhibitors of laminin5beta3 | |
AU6887101A (en) | Copolymers and methods of treating prion-related diseases | |
AUPQ201499A0 (en) | Treatment of inflammatory and malignant diseases | |
AU2001292818A1 (en) | Use of transcription factors for treating inflammation and other diseases | |
AU2002363800A1 (en) | Therapeutic agent composition and method of use | |
AU2001241630A1 (en) | Treatment of inflammation with p20 | |
AU2001226609A1 (en) | Method and formulation for treatment of vasoconstriction |